SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers ...
UCB researchers at work. UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, the companies said, in a deal designed to expand the buyer’s presence in T-cell engager (TCE) antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results